Photo from Yüksel Ürün/X
Dec 11, 2023, 18:34
Yüksel Ürün: Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X/Twitter:
”Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer! In a recent trial, MIRV led to better survival rates and fewer serious adverse events compared to standard chemo. Personalized treatment could be the future!”
For the article click here.
Source: Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18